Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026

Core Insights - Appili Therapeutics has made significant progress in advancing its infectious disease programs, with a focus on securing government funding to support its pipeline [2][4] - The company reported a net loss of CAD$1 million for the third quarter of fiscal year 2026, reflecting a decrease in government assistance and changes in expenses [14] Funding and Financials - Appili has secured over US$75 million in cumulative government funding and has an additional US$82 million in proposals under review [2] - The company received a US$40 million contract from NIAID to advance the development of VXV-01, a dual-antigen vaccine targeting multidrug-resistant Candida species [9][10] - As of December 31, 2025, Appili's cash balance was CAD$0.2 million, down from CAD$1.2 million as of March 31, 2025 [14] Product Development - ATI-1801, a topical formulation for cutaneous leishmaniasis, has a defined registration pathway following positive FDA feedback [3] - LIKMEZ (ATI-1501) has shown commercial momentum in the U.S. market, with steady sales growth since its re-launch in May 2025 [4][5] - ATI-1701, a vaccine candidate for tularemia, achieved key manufacturing milestones and may be eligible for a Priority Review Voucher upon FDA approval [6][7] Market Potential - VXV-01 addresses a critical global health need, with nearly 6.5 million people affected by invasive fungal infections annually, leading to approximately 3.8 million deaths [11]